Editas Q3 Loss Narrows; First Dosing In EDIT-401 Cholesterol Trial On Track For 2026

(RTTNews) - Editas Medicine, Inc. (EDIT) on Monday reported a narrower third-quarter loss as collaboration revenue increased. The gene-editing company also said it remains on track to begin dosing patients in its first clinical trial of EDIT-401 by year-end. Third-Quarter 2026